Oculis Holding
OCS

$11.93

0.17%

Market Cap: $498M

About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Employees: 36

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

22% more funds holding

Funds holding: 9 [Q1] → 11 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

3% less capital invested

Capital invested by funds: $40.9M [Q1] → $39.8M (-$1.11M) [Q2]

1.28% less ownership

Funds ownership: 9.26% [Q1] → 7.98% (-1.28%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$30

151%

upside

Avg. target

$30

151%

upside

High target

$30

151%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Yi Chen

42% 1-year accuracy

59 / 140 met price target

151%upside

$30

Buy

Reiterated

28 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about OCS published over the past 30 days

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with EURETINA, today announced the winner of the Inaugural Ramin Tadayoni Award.

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

Oculis to Present at Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be attending and presenting at the following upcoming investor conferences:

Oculis to Present at Upcoming September Investor Conferences

Oculis Publishes Consolidated Q2 Financial Statements and MD&A

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with the SEC on form 6-K, are attached.

Oculis Publishes Consolidated Q2 Financial Statements and MD&A

Zacks Investment Research

Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates

Oculis Holding AG (OCS) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago.

Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates

Oculis Reports Q2 Financial Results and Provides Recent Company Update

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the quarter ended June 30, 2024, and provided an overview of the Company's progress.

Oculis Reports Q2 Financial Results and Provides Recent Company Update

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the quarter ended June 30, 2024, and provided an overview of the Company's progress.

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be participating at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Oculis and EURETINA Announces the Ramin Tadayoni Award

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces, in collaboration with EURETINA, the Ramin Tadayoni Award.

Oculis and EURETINA Announces the Ramin Tadayoni Award

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action in patients with dry eye disease (DED).

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced positive topline results from its Phase 2b RELIEF trial with licaminlimab, a novel anti-TNFα biologic eye drop with an established dual anti-inflammatory and anti-apoptotic mechanism of action in patients with dry eye disease (DED).

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

See News Rankings